AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04947644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided continuous erector spinae plane block
Description: After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 20 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 10 ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
Study NCT04870073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming
Description: Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
Study NCT04870073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
Study NCT04870073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Priming
Description: The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.
Study NCT04870073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Priming
Description: The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.
Study NCT04855773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEPmate
Description: PrEPmate is a multi-component mHealth intervention grounded in the information, motivation, behavioral skills (IMB) theory of behavior change and developed through user-centered design. PrEPmate promotes personalized communication between patients and providers through interactive weekly check-in messages asking participants how PrEP is going, allowing navigators to identify patients needing more help in taking PrEP, and customized daily pill-taking reminder messages. Trained PrEP navigators reach out to participants who indicate they need assistance via text or phone call and provide tailored support. Additionally, the platform supports 2-way communication between patients and PrEP navigators, including reminders for upcoming clinic visits. Participants are provided links to key information about PrEP (PrEP Basics), and video testimonials of peers taking PrEP. Messages are available in English and Spanish. PrEPmate is aimed at both patients and PrEP navigators.
Study NCT04855773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dot Diary
Description: Dot Diary is a mobile phone app that integrates an electronic pill-taking and sex diary and delivers real-time feedback on PrEP protection. Using the self-management model to increase self-efficacy and patient empowerment, participants log daily PrEP pill-taking and sexual behaviors in the app, which then provides real-time feedback on the level of protection achieved from PrEP (high, medium, low), and customized instructions on doses of PrEP needed to achieve or maintain high protection. Participants can also view a weekly and monthly calendar, including visualizations of the proportion of sex acts covered by PrEP. Finally, the Dot Diary app incorporates gamification components, including an ability to earn sex-positive badges, to increase engagement. Dot Diary is aimed only at patients.
Study NCT03554707 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-53
Description: 2.1 mg DNA/m2 or 2.8 mg DNA/m2 twice weekly
Study NCT03554707 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Standard radiation plan
Study NCT03554707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m2/dose IV daily for five days in a 4-week cycle
Study NCT03554707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100mg/m2 PO daily for five days in a 4-week cycle
Study NCT03554707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg IV every two weeks in a 4-week cycle
Study NCT05004194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular Caloric Stimulation
Description: Irrigation of the right external ear canal
Study NCT04698096 — intervention group
Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
Study NCT05013112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Empagliflozin 20mg once daily from discharge
Study NCT05013112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg twice daily from discharge
Study NCT05013112 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study NCT04698096 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
Study NCT04698096 — intervention group
Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination
Study NCT04843683 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
Study NCT06467136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound production treatment
Description: Evidence based treatment for apraxia of speech, developed by Julie Wambaugh.
Study NCT06467136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery Practice
Description: Practice of target items using motor imagery during home practice
Study NCT05324644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: In the first interviews with the students; It is planned to provide information about acquaintance and research, fill in the scales in 10-15 minutes, make CO measurements, and also conduct an average of 20-40 minutes of motivational interviews in the intervention group. In the second interview in the 1st month, it is planned to summarize the first interview, fill in the scales in 3-5 minutes, make the CO measurements in 10-15 minutes or get the measurement results and apply motivational interview in the average of 20-40 minutes. In the third interview in the 3rd month, it is planned to summarize the second interview in 3-5 min, fill in the scales in 10-15 minutes, make CO measurements or get the measurement results and to apply motivational interviews for an average of 20-40 minutes. In the last interview in the 6th month, it is planned to summarize the 3rd-month interview, to apply the scales for approximately 10-15 minutes, to make CO measurements or to get the measurement results.
Study NCT05548088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LILRB4 STAR-T cells
Description: Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4and-3followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg。
Study NCT05554627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Intranasal spray; a dissociative hallucinogen drug used as a general anesthetic and an antidepressant for treatment of depression.
Study NCT05554627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Atypical antipsychotic; used in the treatment of schizophrenia and bipolar disorder. Other uses include as an add-on treatment in major depressive disorder, tic disorders and irritability associated with autism. Taken by mouth or injection into a muscle.
Study NCT05933538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: The starting dose is 1.5 mg once daily which will be titrated according to the treating psychiatrist who assessing the response with maximum dose of 4.5mg. The dose to be escalated on 2 weekly interval.
Study NCT05933538 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants in this will receive either antidepressants including SSRI, SNRI or TCA or for psychotherapy alone or a combination of psychotherapy and antidepressants.
Study NCT05217810 — intervention group
Intervention type: OTHER
Intervention: Atectura inhalation capsule (150/80ug)
Description: There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT05217810 — intervention group
Intervention type: OTHER
Intervention: Atectura inhalation capsule (150/160ug)
Description: There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT05217810 — intervention group
Intervention type: OTHER
Intervention: Atectura inhalation capsule (150/320ug)
Description: There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT06419712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D (cholecalciferol) supplementation
Description: This clinical pilot study administered and compared daily and bolus dosing regi-mens of vitamin D to achieve and maintain optimal serum levels of 25(OH)D in post-COVID patients. The daily dose group received constant and gradual supplementation of cholecalciferol, intended to achieve more stable 25(OH)D levels without peaks. Conversely, the bolus group received a weekly dose that could lead to rapid increases followed by gradual declines in 25(OH)D levels. The Daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .
Study NCT05052996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL
Description: Capsules administered orally without regard to food
Study NCT05052996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEN
Description: Tablets administered orally without regard to food
Study NCT05052996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Tablets administered orally without regard to food
Study NCT05422066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg on day 1,8,15 for 21 days cycles
Study NCT05422066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction Chemotherapy: 375mg/sqm, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
Study NCT05422066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
Study NCT05422066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
Study NCT05266495 — intervention group
Intervention type: OTHER
Intervention: Brolucizumab
Description: There is no treatment allocation. Patients administered brolucizumab by prescription will be enrolled.
Study NCT06150261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AvailOm
Description: 5 capsules taken once daily with main meal
Study NCT06150261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 capsules taken once daily with main meal
Study NCT05621733 — intervention group
Intervention type: OTHER
Intervention: ruxolitinib
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with ruxolitinib in the commercial setting are eligible to enroll into this study.
Study NCT04740567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The cognitive training program regimen and its degree of difficulty will be tailored to the patient's current level of cognitive functioning and interests. Patients will be asked to work through progressively more challenging exercises pertaining to orientation, attention, problem-solving, and memory. These cognitive training exercises will be significantly difficult but when they can be completed easily (>85% mastery), their difficulty will be increased, and this process will be repeated as appropriate. They will also perform puzzles, games, or cognitive tasks related to their hobbies.
Study NCT04740567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Goal management training will (1) teach patients compensatory strategies such as stop techniques \[e.g., to stop and think about consequences of a decision before making it\]; (2) help them to take complex tasks and divide them into manageable subtasks to increase the likelihood of completing the task; and (3) enable them to learn to regain cognitive control when their behavior becomes incompatible with their intended goals. GMT is anchored in sustained and vigilant attention theory and it enables patients to actively attend to higher order goals critical to functioning. GMT is tailored to the individual needs of the patient. During the initial session, the Cognitive Intervention Specialist will meet with the subject and their family member or caregiver to identify these functional and cognitive deficiencies.
Study NCT05422066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
Study NCT05422066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
Study NCT06266403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Communicative Interaction
Description: Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the ____ this time, and the listener will click on it. After the listener has made their selection, both participants will receive feedback on trial success.
Study NCT06266403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clear Speech
Description: PALS and age-matched speakers will read critical words consisting of target segments (e.g., hid, ship, net) in random order four times. These words will be embedded in the carrier phrase Click on the ___ this time. Participations will be instructed to overenunciate the critical words.
Study NCT06266403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unstructured communicative interaction
Description: Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. The pairs will be presented with two different versions of the same picture with eight differences chosen to elicit the same target segments (e.g., hid, ship, net). These pictures will be modified from the LUCID corpus. In total, pairs will complete four picture sets per session. Pairs will be given 5 minutes for each picture set.
Study NCT06266403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clear Speech Structured Communicative Interaction
Description: Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the ____ this time, and the listener will click on it. The speaker will be instructed to overenunciate the critical words. After the listener has made their selection, both participants will receive feedback on trial success.
Study NCT06496412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: Take fecal microbiota capsules.
Study NCT06496412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take placebo capsules.
Study NCT05147480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: internet-based mother-baby yoga
Description: Mother-baby yoga group classes given by physiotherapists via Zoom Video Communications
Study NCT05112887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Therapy
Description: Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.
Study NCT05112887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Osteopathic Manipulative Therapy
Description: Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.
Study NCT04428047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bintrafusp alfa
Description: bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
Study NCT06173999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554/CHOP
Description: SHR2554 with CHOP
Study NCT06173999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554/CHOEP
Description: SHR2554 with CHOEP
Study NCT05845359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: One group will receive 10mg of methadone upon induction, while the other will receive a saline solution as placebo. We will see the effectiveness of methadone on postoperative pain management, while monitoring for opioid-related side effects.
Study NCT05973136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program based on cardiorespiratory principles
Description: The intervention consists of a hybrid program. The participant will receive rehabilitation sessions in presence (aerobic component of the intervention based on maximal oxygen uptake measured before intervention by means on a ergospirometric test) and at home via a telerehabilitation platform. The length of the intervention is 12 weeks. For the in-presence sessions, they are going to be 75 minutes, 2x/week. For the at-distance sessions, they are going to be 45 minutes, 1x/week in groups of 3 to 4 participants. The intervention will consist of a warm-up, endurance, postural, and strengthening exercises, cool down and respiratory exercises. An exercise book with final recommendations is provided to the participants at the end of the intervention.
Study NCT06064344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intralesional Rituximab Injection
Study NCT06064344 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved Site Radiation Therapy
Description: Involved Site Radiation Therapy
Study NCT05033392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: A domestic PD-1 antibody
Study NCT06547476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib
Description: Tucidinostat (chidamide)，30mg, po., biw PD-1 inhibitor (tislelizumab), 200mg, ivgtt. d1, q3w anlotinib, 12mg, po., d1-14, q3w
Study NCT06303661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ablative Radiofrequency
Description: There are two electrodes: one active, which will be used on the penis, using a non-lubricated condom from the Blowtex brand, using pharmaceutical glycerin to emit radiofrequency inside and outside the condom, and another electrode, dispersive, wrapped in PVC-type plastic film, coupled to the region of the patient's penis where there is no fibrotic plaque, which will act as earth and the temperature to be used in the treatment will be 38°C. When the desired heating is reached, the device maintains the temperature and thus the radiofrequency application will be maintained for 2 minutes.